For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$44.59
Thesis
Zealand Pharma is a Danish peptide developer building an obesity portfolio around amylin, GLP-1, and multi-agonist mechanisms. Petrelintide — an amylin analog in Phase 3 — is the lead asset and gives Zealand a differentiated mechanism that pairs naturally with GLP-1s rather than competing head-on with them. The Boehringer Ingelheim partnership on survodutide validates the platform.
The primary listing is Nasdaq Copenhagen (ZEAL), where institutional volume sits. US-listed instruments exist but trade thinly; market data for the primary listing isn't on our current US market-data provider, so price and market cap will show as "—" until a non-US source is wired in.
Catalysts
- Petrelintide Phase 3 data readouts in obesity
- Survodutide regulatory progress (Boehringer-led)
- Pipeline expansion into adjacent metabolic indications
- Potential US dual-listing or expanded analyst coverage